Loss from operations for the three months ended December 31, 2023, was $16.2M, an increase of 39% compared to fourth quarter 2022. “In 2023, we made significant progress on cost controls and in the development of our transplant monitoring IP,” said Josh Riggs, CEO of Oncocyte. “We achieved reimbursement for VitaGraft Kidney, manufactured the first lots of GraftAssure RUO, and ran a competitive partnering process that resulted in the announced Bio-Rad agreement. We look forward to working with them on the commercialization of GraftAssure RUO and the development of VitaGraft Kidney IVD. We continue to benefit from strong support from our core investors and welcome new ones in our recently completed $15.8 million private placement offering. With this partnership and financing we believe that we are well-positioned to meet our critical commercial and regulatory milestones.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCX:
- Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
- Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
- OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Two new option listings and option delistings on February 26th